153 related articles for article (PubMed ID: 26801062)
1. Circulating soluble receptor for advanced glycation end products is decreased and inversely associated with acute phase response in chronic spontaneous urticaria.
Kasperska-Zajac A; Damasiewicz-Bodzek A; Tyrpień-Golder K; Zamlyński J; Grzanka A
Inflamm Res; 2016 May; 65(5):343-6. PubMed ID: 26801062
[TBL] [Abstract][Full Text] [Related]
2. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
Basta G; Del Turco S; Navarra T; Lee WM;
Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
[TBL] [Abstract][Full Text] [Related]
4. Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD.
Meijer B; Hoskin T; Ashcroft A; Burgess L; Keenan JI; Falvey J; Gearry RB; Day AS
J Crohns Colitis; 2014 Jun; 8(6):513-20. PubMed ID: 24291021
[TBL] [Abstract][Full Text] [Related]
5. The association between platelet count and acute phase response in chronic spontaneous urticaria.
Kasperska-Zając A; Grzanka A; Jarzab J; Misiołek M; Wyszyńska-Chłap M; Kasperski J; Machura E
Biomed Res Int; 2014; 2014():650913. PubMed ID: 25025065
[TBL] [Abstract][Full Text] [Related]
6. Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Grzanka A; Damasiewicz-Bodzek A; Szumska M; Kasperska-Zajac A
J Biol Regul Homeost Agents; 2017; 31(2):407-411. PubMed ID: 28685545
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma il-8 concentration is related to severity of systemic inflammation in chronic spontaneous urticaria.
Kasperska-Zajac A; Grzanka A; Damasiewicz-Bodzek A; Bieniek K; Skrzypulec-Frankel A; Stencel-Gabriel K; Sikora-Zydek A
J Biol Regul Homeost Agents; 2017; 31(4):957-961. PubMed ID: 29254299
[TBL] [Abstract][Full Text] [Related]
8. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease.
Chen DY; Chen YM; Lin CC; Hsieh CW; Wu YC; Hung WT; Chen HH; Lan JL
BMC Musculoskelet Disord; 2015 May; 16():111. PubMed ID: 25956266
[TBL] [Abstract][Full Text] [Related]
9. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria.
Kasperska-Zajac A; Grzanka A; Misiolek M; Mazur B; Machura E
Cytokine; 2015 Dec; 76(2):566-568. PubMed ID: 25982553
[TBL] [Abstract][Full Text] [Related]
10. Elevated circulating heat shock protein 70 and its antibody concentrations in chronic spontaneous urticaria.
Kasperska-Zając A; Damasiewicz-Bodzek A; Bieniek K; Skrzypulec-Frankel A; Tyrpien-Golder K; Grzanka A
Int J Immunopathol Pharmacol; 2018; 31():394632017750440. PubMed ID: 29268639
[TBL] [Abstract][Full Text] [Related]
11. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
[TBL] [Abstract][Full Text] [Related]
12. Reduced soluble receptor for advanced glycation end-products in COPD.
Smith DJ; Yerkovich ST; Towers MA; Carroll ML; Thomas R; Upham JW
Eur Respir J; 2011 Mar; 37(3):516-22. PubMed ID: 20595148
[TBL] [Abstract][Full Text] [Related]
13. Effect of S100A12 and soluble receptor for advanced glycation end products on the occurrence of severe acute pancreatitis.
Zhao B; Chen Y; Sun WW; Chen WW; Ma L; Yang ZT; Huang J; Chen EZ; Fei J; Mao EQ
J Dig Dis; 2016 Jul; 17(7):475-82. PubMed ID: 27251034
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism.
Caspar-Bell G; Dhar I; Prasad K
Mol Cell Biochem; 2016 Mar; 414(1-2):171-8. PubMed ID: 26895319
[TBL] [Abstract][Full Text] [Related]
15. Chronic spontaneous urticaria is characterized by lower serum advanced glycation end-products.
Grzanka A; Damasiewicz-Bodzek A; Machura E; Szumska M; Tyrpień-Golder K; Mazur B; Kasperska-Zajac A
Biomed Res Int; 2014; 2014():974154. PubMed ID: 25180195
[TBL] [Abstract][Full Text] [Related]
16. Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome.
Jensen LJ; Flyvbjerg A; Bjerre M
Biomed Res Int; 2015; 2015():815942. PubMed ID: 26491690
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects.
Hagen I; Schulte DM; Müller N; Martinsen J; Türk K; Hedderich J; Schreiber S; Laudes M
Cytokine; 2015 Jun; 73(2):265-9. PubMed ID: 25802195
[TBL] [Abstract][Full Text] [Related]
18. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
[TBL] [Abstract][Full Text] [Related]
19. Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes.
Lee AC; Lam JK; Shiu SW; Wong Y; Betteridge DJ; Tan KC
PLoS One; 2015; 10(9):e0137330. PubMed ID: 26325204
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble LIGHT/TNFSF14 is increased and associated with IL-8 concentration in chronic spontaneous urticaria.
Kasperska-Zając A; Damasiewicz-Bodzek A; Grzanka R; Skrzypulec-Frankel A; Bieniek K; Sikora-Żydek A; Jochem J
Int J Immunopathol Pharmacol; 2018; 32():2058738418784431. PubMed ID: 29952668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
